Allergopharma GmbH & Co. KG
Quick facts
Marketed products
- House dust mite Novo Helisen Depot · Immunology / Allergy
House dust mite allergen extract that desensitizes the immune system through repeated subcutaneous administration to reduce allergic responses. - wasp venom · Immunology / Allergy
Wasp venom contains allergenic proteins that are used in allergen immunotherapy to desensitize patients to wasp stings by inducing immune tolerance.
Phase 3 pipeline
- Acaroid · Other
- AL0704rP · Immunology / Allergy
AL0704rP is an allergen immunotherapy designed to modulate immune tolerance to specific allergens through controlled exposure and immune desensitization. - Allerslit forte · Immunology / Allergy
Allerslit forte is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual exposure to increasing doses. - Birch pollen allergoid · Immunology / Allergy
Birch pollen allergoid is a modified birch pollen extract that induces immune tolerance to birch pollen allergens through gradual desensitization. - Grass pollen formulation · Immunology / Allergy
A grass pollen allergen extract that desensitizes the immune system to grass pollen allergens through repeated controlled exposure. - Grass pollen specific immunotherapy · Immunology
Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance. - Recombinant birch pollen · Immunology / Allergy
Recombinant birch pollen allergen extract desensitizes the immune system to birch pollen through repeated controlled exposure, reducing allergic responses. - recombinant birch pollen allergen · Immunology / Allergy
Recombinant birch pollen allergen is used in allergen immunotherapy to desensitize the immune system to birch pollen by inducing tolerance through repeated controlled exposure to the allergen. - Recombinant grass pollen · Immunology / Allergy
Recombinant grass pollen allergen extract desensitizes the immune system to grass pollen by inducing immune tolerance through repeated controlled exposure.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: